SOURCE: Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc.

September 27, 2010 09:00 ET

Cleveland BioLabs to Present at 9th Annual BIO Investor Forum

BUFFALO, NY--(Marketwire - September 27, 2010) -  Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the 9th Annual BIO Investor Forum, October 5-6, in San Francisco, CA.

Michael Fonstein, Ph.D., Chief Executive Officer and President of Cleveland BioLabs, will give a presentation on October 6 at 11:00 a.m. Pacific Daylight Time / 2:00 p.m. Eastern Daylight Time. A copy of the presentation will be available on the Company's website, www.cbiolabs.com, in the Investors section. 

Cleveland BioLabs is developing a pipeline of products for multiple defense and medical applications from two primary families of compounds: Protectans and Curaxins. Protectans are being developed as drug candidates that protect normal tissues from acute stresses such as radiation and chemotherapy. Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer agents. 

For more information about the 9th Annual BIO Investor Forum, please visit
www.bio.org/investorforum.

About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at http://www.cbiolabs.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors.

These factors include, among others, the Company's history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern; the Company's need for substantial additional financing to meet its business objectives; the potential for the loss of funding from the Company's R&D grants and contracts; the Company's failure to successfully and timely develop new products; the risks inherent in the early stages of drug development and in conducting clinical trials; the Company's inability to obtain regulatory approval in a timely manner or at all; the Company's collaborative relationships and the financial risks related thereto; the Company's ability to comply with its obligations under license agreements; the potential for significant product liability claims; and the Company's ability to comply with various safety, environmental and other governmental regulations. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the "Risk Factors" and "Forward-Looking Statements" described in the Company's periodic filings with the Securities and Exchange Commission.

Contact Information

  • Contact:
    Rachel Levine
    Director Corporate Development & Communications
    Cleveland BioLabs, Inc.
    T: (646) 284-9439
    E: rlevine@cbiolabs.com